Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|17|10|1025-1035

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.17, Iss.10, 2011-04, pp. : 1025-1035

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

VIP and PACAP in pain and inflammation

By Said S.I.S.I.  

Trends in Pharmacological Sciences, Vol. 21, Iss. 2, 2000-02 ,pp. : 57-57

Elsevier

Access to resources Recommend Favorite

VIP and PACAP: very important in pain?

By Dickinson T.   Fleetwood-Walker S.M.  

Trends in Pharmacological Sciences, Vol. 20, Iss. 8, 1999-08 ,pp. : 324-329

Elsevier

Access to resources Recommend Favorite

Animal models of multiple sclerosis

By  

PHARMAKON, Vol. 2, Iss. 6, 2014-11 ,pp. : 429-434

Govi-Verlag

Access to resources Recommend Favorite

Interaction of lipophilic VIP derivatives with recombinant VIP 1 /PACAP and VIP 2 /PACAP receptors

By Gourlet P.   Rathe J.   De Neef P.   Cnudde J.   Vandermeers-Piret M.-C.   Waelbroeck M.   Robberecht P.  

European Journal of Pharmacology, Vol. 354, Iss. 1, 1998-07 ,pp. : 105-111

Elsevier

Access to resources Recommend Favorite

Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness

By Clegg A.   Bryant J.  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 4, 2001-04 ,pp. : 623-639

Informa Healthcare

Access to resources Recommend Favorite